Mitochondrial dysfunction therapeutic - Stealth BioTherapeutics
Latest Information Update: 28 Sep 2022
At a glance
- Originator Stealth BioTherapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mitochondrial disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Mitochondrial disorders in USA
- 14 Aug 2018 Preclinical trials in Mitochondrial disorders in USA (unspecified route)
- 14 Aug 2018 Stealth BioTherapeutics plans clinical trials trial for mitochondrial disorders in 2019